Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 18/20 | 0.55 |
| ▸ | RAB9A | P51151 | 18/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179168 | 0.92 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL2996048 | 0.86 | PIK3CG (0.58) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL7968545 | 0.85 | PIK3CG (0.57) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL18863906 | 0.82 | PIK3CG (0.67) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1178306 | 0.82 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1178624 | 0.82 | PIK3CG (0.67) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL18877818 | 0.81 | PIK3CG (0.65) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL18863909 | 0.81 | PIK3CG (0.65) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1178858 | 0.81 | PIK3CG (0.57) | NPC1RAB9ASMN1; SMN2PIK3CGTSHR | |
| SCHEMBL1178249 | 0.79 | PIK3CG (0.51) | NPC1RAB9ASMN1; SMN2HPGDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148372-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| EP-2303872-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-12-16 | — | — | US | claimed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | claimed |
| EP-2772492-B1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | ASTRAZENECA AB (SE) | 2016-08-17 | — | — | EP | disclosed |
| EP-2772492-B1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | ASTRAZENECA AB (SE) | 2016-08-17 | — | — | EP | disclosed |
| EP-2772492-A1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | AstraZeneca AB (SE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2772492-A1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | AstraZeneca AB (SE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2303872-B1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2303872-B1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2014-04-16 | — | — | EP | disclosed |
| US-8148372-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148372-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-7781434-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | NPC1 2154/4885RAB9A 3344/4885SMN1; SMN2 2498/4885 |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | GRM1, GRM3, GRIN1 | NPC1 2192/4885RAB9A 3167/4885SMN1; SMN2 2377/4885 |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | NPC1 2154/4885RAB9A 3344/4885SMN1; SMN2 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.